In Germany,<unk>  is marketed for the treatment of psoriasis and is available as an oral formulation mixed with related compounds (Fumaderm); in the UK, it is available as a pure oral formulation (Skilarence). It is also available in the U.S. as an oral formulation (Tecfidera) to treat adults with relapsing multiple sclerosis. For the treatment of psoriasis,<unk>  is dosed in 30 mg and 120 mg tablets, and the maximum daily dose is 720 mg. For multiple sclerosis, the doses are 120 mg and 240 mg , with a maximum daily dose of 480 mg. A 2015 Cochrane systematic review found moderate quality evidence of a reduction in the number of people with relapsing remitting MS that had relapses over a two-year treatment period with<unk>  versus placebo, as well as low quality evidence of a reduction in worsening disability, and an overall need for higher quality studies with longer follow-up.<unk>  is being evaluated as a treatment for COVID-19 as part of the RECOVERY Trial in the UK.
Dimethyl fumarate
Bisacodyl
Colestyramine
Sulforaphane
Nepafenac
Docusate
Tegaserod
Cimetidine